Arteriosclerosis and Thrombosis, Vol 11, 1830-1843, Copyright © 1991 by American Heart Association

ARTICLES

Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation

TM Bocan, SB Mueller, PD Uhlendorf, RS Newton and BR Krause
Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Mich. 48105.

Due to the potential importance of acyl-coenzyme A:cholesterol O- acyltransferase (ACAT) in the generation of lipid-filled monocytes- macrophages, the ACAT inhibitor CI-976 (2,2-dimethyl-N-(2,4,6- trimethoxyphenyl)dodecanamide) was evaluated relative to selected lipid- lowering agents for their effect on atherosclerotic lesion regression and progression. Atherosclerotic lesions comparable in composition to human fatty streaks were induced by chronic endothelial denudation in the iliac-femoral artery of hypercholesterolemic New Zealand White rabbits before intervention, while naturally occurring fatty streaks developed in the thoracic aorta. CI-976 administered in a hypercholesterolemic diet at a dose that did not lower plasma cholesterol prevented the accumulation of monocytes-macrophages within the preestablished iliac-femoral lesion and reduced the foam cell area by 27-29% relative to the initiation of intervention. CI-976 also blunted the development of thoracic aortic fatty streak-like lesions and decreased the cholesteryl ester enrichment by 46%. CI-976 had no effect on plasma triglycerides and, more importantly, had no effect or decreased liver, iliac-femoral, and thoracic aortic free cholesterol content. Dietary intervention alone increased monocyte-macrophage involvement in the iliac-femoral lesion despite reductions in plasma, liver, and thoracic aortic cholesterol content. Conventional lipid- lowering therapy such as cholestyramine or cholestyramine/niacin required substantial decreases in plasma cholesterol levels to achieve comparable vascular changes. We conclude that inhibition of ACAT within the arterial wall by the potent and specific ACAT inhibitor CI-976, even in the absence of plasma cholesterol lowering, can result in the inhibition of atherosclerotic lesion progression and can enhance regression.

This article has been cited by other articles:

				Y. Fujiwara, N. Kiyota, M. Hori, S. Matsushita, Y. Iijima, K. Aoki, D. Shibata, M. Takeya, T. Ikeda, T. Nohara, et al. Esculeogenin A, a New Tomato Sapogenol, Ameliorates Hyperlipidemia and Atherosclerosis in ApoE-Deficient Mice by Inhibiting ACAT Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2400 - 2406. [Abstract] [Full Text] [PDF]

				Y. Wang, A. B. Castoreno, W. Stockinger, and A. Nohturfft Modulation of Endosomal Cholesteryl Ester Metabolism by Membrane Cholesterol J. Biol. Chem., March 25, 2005; 280(12): 11876 - 11886. [Abstract] [Full Text] [PDF]

				N. D. Vaziri and K. Liang ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure Am J Physiol Renal Physiol, November 1, 2004; 287(5): F1038 - F1043. [Abstract] [Full Text] [PDF]

				H. Wergedahl, B. Liaset, O. A. Gudbrandsen, E. Lied, M. Espe, Z. Muna, S. Mork, and R. K. Berge Fish Protein Hydrolysate Reduces Plasma Total Cholesterol, Increases the Proportion of HDL Cholesterol, and Lowers Acyl-CoA:Cholesterol Acyltransferase Activity in Liver of Zucker Rats J. Nutr., June 1, 2004; 134(6): 1320 - 1327. [Abstract] [Full Text] [PDF]

				J. Kusunoki, D. K. Hansoty, K. Aragane, J. T. Fallon, J. J. Badimon, and E. A. Fisher Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, May 29, 2001; 103(21): 2604 - 2609. [Abstract] [Full Text] [PDF]

				D. J. M. Delsing, E. H. Offerman, W. van Duyvenvoorde, H. van der Boom, E. C. M. de Wit, M. J. J. Gijbels, A. van der Laarse, J. W. Jukema, L. M. Havekes, and H. M. G. Princen Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice Circulation, April 3, 2001; 103(13): 1778 - 1786. [Abstract] [Full Text] [PDF]

				K. Aragane, K. Fujinami, K. Kojima, and J. Kusunoki ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits J. Lipid Res., April 1, 2001; 42(4): 480 - 488. [Abstract] [Full Text]

				D. G. Robertson, M. A. Breider, and M. A. Milad Preclinical Safety Evaluation of Avasimibe in Beagle Dogs: An ACAT Inhibitor with Minimal Adrenal Effects Toxicol. Sci., February 1, 2001; 59(2): 324 - 334. [Abstract] [Full Text] [PDF]

				R. G. Lee, M. C. Willingham, M. A. Davis, K. A. Skinner, and L. L. Rudel Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates J. Lipid Res., December 1, 2000; 41(12): 1991 - 2001. [Abstract] [Full Text]

				C. W. Joyce, G. S. Shelness, M. A. Davis, R. G. Lee, K. Skinner, R. A. Anderson, and L. L. Rudel ACAT1 and ACAT2 Membrane Topology Segregates a Serine Residue Essential for Activity to Opposite Sides of the Endoplasmic Reticulum Membrane Mol. Biol. Cell, November 1, 2000; 11(11): 3675 - 3687. [Abstract] [Full Text]

				T. M. A. Bocan, B. R. Krause, W. S. Rosebury, S. B. Mueller, X. Lu, C. Dagle, T. Major, C. Lathia, and H. Lee The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 70 - 79. [Abstract] [Full Text] [PDF]

				J. X. Rong, L. Shen, Y. H. Chang, A. Richters, H. N. Hodis, and A. Sevanian Cholesterol Oxidation Products Induce Vascular Foam Cell Lesion Formation in Hypercholesterolemic New Zealand White Rabbits Arterioscler Thromb Vasc Biol, September 1, 1999; 19(9): 2179 - 2188. [Abstract] [Full Text] [PDF]

				A. Rodriguez, P. S. Bachorik, and S.-B. Wee Novel Effects of the Acyl-Coenzyme A:Cholesterol Acyltransferase Inhibitor 58-035 on Foam Cell Development in Primary Human Monocyte–Derived Macrophages Arterioscler Thromb Vasc Biol, September 1, 1999; 19(9): 2199 - 2206. [Abstract] [Full Text] [PDF]

				L. J. Wilcox, P. H. R. Barrett, R. S. Newton, and M. W. Huff ApoB100 Secretion From HepG2 Cells is Decreased by the ACAT Inhibitor CI-1011 : An Effect Associated With Enhanced Intracellular Degradation of ApoB Arterioscler Thromb Vasc Biol, April 1, 1999; 19(4): 939 - 949. [Abstract] [Full Text] [PDF]

				J.-L. Escary, H. A. Choy, K. Reue, X.-P. Wang, L. W. Castellani, C. K. Glass, A. J. Lusis, and M. C. Schotz Paradoxical effect on atherosclerosis of hormone-sensitive lipase overexpression in macrophages J. Lipid Res., March 1, 1999; 40(3): 397 - 404. [Abstract] [Full Text]

				S. Cases, S. Novak, Y.-W. Zheng, H. M. Myers, S. R. Lear, E. Sande, C. B. Welch, A. J. Lusis, T. A. Spencer, B. R. Krause, et al. ACAT-2, A Second Mammalian Acyl-CoA:Cholesterol Acyltransferase. ITS CLONING, EXPRESSION, AND CHARACTERIZATION J. Biol. Chem., October 9, 1998; 273(41): 26755 - 26764. [Abstract] [Full Text] [PDF]

				A. Miyazaki, N. Sakashita, O. Lee, K. Takahashi, S. Horiuchi, H. Hakamata, P. M. Morganelli, C. C. Y. Chang, and T.-Y. Chang Expression of ACAT-1 Protein in Human Atherosclerotic Lesions and Cultured Human Monocytes-Macrophages Arterioscler Thromb Vasc Biol, October 1, 1998; 18(10): 1568 - 1574. [Abstract] [Full Text] [PDF]

				I.J. Martins, B.-C. Mortimer, and T.G. Redgrave Effect of the ACAT Inhibitor CL 277,082 on Apolipoprotein B48 Transport in Mesenteric Lymph and on Plasma Clearance of Chylomicrons and Remnants Arterioscler Thromb Vasc Biol, January 1, 1997; 17(1): 211 - 216. [Abstract] [Full Text]

				N. Duverger, C. Viglietta, L. Berthou, F. Emmanuel, A. Tailleux, L. Parmentier-Nihoul, B. Laine, C. Fievet, G. Castro, J. C. Fruchart, et al. Transgenic Rabbits Expressing Human Apolipoprotein A-I in the Liver Arterioscler Thromb Vasc Biol, December 1, 1996; 16(12): 1424 - 1429. [Abstract] [Full Text]

				N. Duverger, H. Kruth, F. Emmanuel, J.-M. Caillaud, C. Viglietta, G. Castro, A. Tailleux, C. Fievet, J. C. Fruchart, L. M. Houdebine, et al. Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits Circulation, August 15, 1996; 94(4): 713 - 717. [Abstract] [Full Text]

				J. R. Guyton and K. F. Klemp Development of the Lipid-Rich Core in Human Atherosclerosis Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 4 - 11. [Full Text]

				H. Yagyu, T. Kitamine, J.-i. Osuga, R.-i. Tozawa, Z. Chen, Y. Kaji, T. Oka, S. Perrey, Y. Tamura, K. Ohashi, et al. Absence of ACAT-1 Attenuates Atherosclerosis but Causes Dry Eye and Cutaneous Xanthomatosis in Mice with Congenital Hyperlipidemia J. Biol. Chem., July 7, 2000; 275(28): 21324 - 21330. [Abstract] [Full Text] [PDF]

				S. Sonda, L.-M. Ting, S. Novak, K. Kim, J. J. Maher, R. V. Farese Jr., and J. D. Ernst Cholesterol Esterification by Host and Parasite Is Essential for Optimal Proliferation of Toxoplasma gondii J. Biol. Chem., September 7, 2001; 276(37): 34434 - 34440. [Abstract] [Full Text] [PDF]

				K. K. Buhman, H. C. Chen, and R. V. Farese Jr. The Enzymes of Neutral Lipid Synthesis J. Biol. Chem., October 26, 2001; 276(44): 40369 - 40372. [Full Text] [PDF]